logo
logo
  • Home
  • Request Uromonitor
  • Press
  • Contact us
  • Login
  • English
    • English
    • Português
    • Español
    • Français
    • Deutsch
https://uromonitor.com/wp-content/uploads/video-veris-compressed.mp4

Promotional UroMonitor

January 31, 2018
|In Business
|By uromonitor
https://uromonitor.com/wp-content/uploads/video-veris-compressed.mp4
  • Prev
  • Next

PRESS

  • IN TIMES OF COVID19, CANCER PATIENTS HAVE A NEW WAY TO AVOID DELAYING DIAGNOSTIC PROCEDURES AND SURVEILLANCE OF BLADDER TUMOURS. May 21, 2020
  • TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients February 5, 2020
  • Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review February 5, 2020
  • Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study February 5, 2020
  • Uromonitor as a Novel Sensitive and Specific Urine-based Test for Recurrence Surveillance of Patients with Non-muscle Invasive Bladder Cancer – Article in URO Today October 6, 2018

VALUE PROPOSITION

“For persons at risk or patients diagnosed with bladder cancer, as well as their urologist, who have the need of more convenient surveillance methods, Uromonitor is a completely non-invasive, urine-based, In vitro Diagnosis (IVD) kit that is able to detect bladder cancer with high sensitivity and specificity.

Uromonitor is easy and can deliver reliable results to reducecostswithfollow-up”.

© UROMONITOR